Dr Peter Campbell is Head of Cancer Genetics and Genomics at the Institute and is joint head of the Cancer Genome Project. His research focuses on the use of next-generation sequencing technologies for annotating cancer genomes. He is also a practising haematologist at Addenbrooke's Hospital in Cambridge.
After completing his specialist training in Haematology in 2002 in Australia and New Zealand, Peter earned his PhD into the molecular pathogenesis and clinical management of myeloproliferative disorders at the University of Cambridge. Peter remains co-clinical lead on the largest randomised clinical trial in essential thrombocythaemia, a common chronic haematological malignancy.
In 2007 Peter moved to the Sanger Institute where he joined the Cancer Genome Project on a Kay Kendall Leukaemia Fund Clinical Fellowship. Since joining the Institute, he has pioneered the development of protocols for identifying somatically acquired mutations from massively parallel sequencing data. In 2009 Peter was senior author on the first complete high-coverage sequence and analysis of a whole cancer genome associated with tobacco smoke exposure.